Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Effects of the CCKB antagonist L-365, 260 on benzodiazepine withdrawal-induced hypophagia in rats


The effect of the selective CCKB antagonist L-365, 260 on chlordiazepoxide (CDP) withdrawal-induced hypophagia was assessed in two related studies in rats pretreated for 21 days with CDP at doses escalated from 10 to 30 mg/kg per day (b.i.d.). L-365, 260 was studied at doses from 0.001 to 10 mg/kg (b.i.d.). There was no evidence that L-365, 260 at any dose alleviated CDP withdrawal-induced hypophagia. These data contrast with reports that CCKB antagonists alleviate behavioural benzodiazepine (BZ) withdrawal symptoms considered to be indicative of “anxiogenesis”. Presumably, such positive effects of CCKB antagonists are due to “functional antagonism”, with enhanced anxiety during BZ withdrawal being attenuated by anxiolytic actions of CCKB antagonists. Collectively, studies with CCKB antagonists and other agents involving a number of different BZ withdrawal signs suggest that BZ withdrawal is a heterogeneous syndrome, with various different underlying mechanisms. CCKB antagonists appear to alleviate only a subset of possible BZ withdrawal signs.


  1. Andrews N, File SE (1993) Increased 5-HT release mediates the anxiogenic response during benzodiazepine withdrawal: a review of supporting neurochemical and behavioural evidence. Psychopharmacology 112:21–25

  2. Baldwin HA, File SE (1988) Reversal of increased anxiety during benzodiazepine withdrawal: evidence for an anxiogenic endogenous ligand for the benzodiazepine receptor. Brain Res Bull 20:603–606

  3. Barnes NM, Costall B, Domeney AM, Gerrard PA, Kelly ME, Khraling H, Naylor RJ, Tompkins DM, Williams TJ (1991) The effects of umespirone as a potential anxiolytic and antipsychotic agent. Pharmacol Biochem Behav 40:89–96

  4. Bradwejn J, De Montigny C (1984) Benzodiazepines antagonise cholecystokinin-induced activation of rat hippocampal neurones. Nature 312:363–364

  5. Costall B, Domeney AM, Gerrard PA, Jones BJ, Kelley ME, Oakley NR, Tyers MB (1989a) The anxiolytic activities of the 5-HT3 receptor antagonists GR38032F, ICS 205-930 and BRL 43694. In: Bevan P, Cools AR, Archer T (eds) Behavioural pharmacology of 5-HT. Lawrence Erlbaum Associates, Hillsdale, New Jersey, p 383

  6. Costall B, Jones BJ, Kelly ME, Naylor RJ, Oakley NR, Onaivi ES, Tyers MB (1989b) The effects of ondansetron (GR38032F) in rats and mice treated subchronically with diazepam. Pharmacol Biochem Behav 34:769–778

  7. Costall B, Domeney AM, Gerrard PA, Horrovitz ZP, Kelly ME, Naylor RJ, Tompkins DM (1990a) Effects of captropil and SQ,29,852 on anxiety-related behaviours in rodent and marmoset. Pharmacol Biochem Behav 36:13–20

  8. Costall B, Kelly ME, Naylor RJ, Onaivi ES (1990b) The effects of ketotifen in rodent models of anxiety and on the behavioural consequences of withdrawing from treatment with drugs of abuse. Naunyn Schmeideberg's Ach Pharmacol 341:547–551

  9. Costall B, Domeney AM, Farre AJ, Kelly ME, Martinez L, Naylor RJ (1992) Profile of action of the novel 5-HT1A receptor ligand E-4424 to inhibit aversive behaviour in the mouse, rat and marmoset. J Pharmacol Exp Ther 262:90–98

  10. Dooley DJ, Klamt I (1993) Differential profile of the CCKB antagonist CI988 and diazepam in the four-plate test. Psychopharmacology 112:452–454

  11. Dourish CT, Rycroft W, Iversen SD (1989) Postponement of satiety by blockade of brain cholecystokinin (CCK-B) receptors. Science 245:1509–1511

  12. Dourish CT, O'Neill MF, Coughlan J, Kitchener SJ, Hawley D, Iversen SD (1990) The selective CCK B receptor antagonist L-365, 260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol 176:35–44

  13. File SE, Andrews N (1991) Low but not high doses of buspirone reduce the anxiogenic effects of diazepam withdrawal. Psychopharmacolgy 105:578–582

  14. File SE, Mabbutt PS, Andrews N (1991) Diazepam withdrawal responses measured in the social interaction test of anxiety and their reversal by baclofen. Psychopharmacology 104:62–66

  15. Goudie AJ, Leathley MJ (1990) Effects of the 5-HT3 antagonist GR38032F (ondansetron) on benzodiazepine withdrawal in rats. Eur J Pharmacol 185:179–184

  16. Goudie AJ, Leathley MJ (1991a) An evaluation of the dependence potential of the selective 5-HT1A agonist ipsapirone in rats and its effects on benzodiazepine withdrawal. Psychopharmacology 103:529–537

  17. Goudie AJ, Leathley MJ (1991b) Effects of the 5-HT1A agonist gepirone on benzodiazepine withdrawal in rats. Behav Pharmacol 2:461–469

  18. Goudie AJ, Leathley MJ (1992) Operant “behavioural dependence” studies with chlordiazepoxide in rats: lack of effect of ondansetron. Psychopharmacology 109:461–465

  19. Goudie AJ, Leathley MJ (1994) Assessment of the dependence potential of the potent high-efficacy 5-HT1A agonist anxiolytic S-14506 in rats. J Psychopharmacology (in press)

  20. Goudie AJ, Harrison AA, Leathley MJ (1993) Evidence for a dissociation between benzodiazepine withdrawal signs. Neuro Report 4: 295–298

  21. Goudie AJ, Leathley MJ, Cowgill J (1994) Assessment of the benzodiazepine-like dependence potential of the putative 5-HT1A agonist anxiolytic S-20499 in rats. Behav Pharmacol 5: 131–140

  22. Harro J, Pold M, Vasar E (1990a) Anxiogenic-like actions of caerulein, a CCK-8 receptor agonist, in the mouse. Influence of acute and subchronic diazepam treatment. Naunyn-Schmiedeberg's Arch Pharmacol 341: 62–67

  23. Harro J, Lang A, Vasar E (1990b) Long term diazepam treatment produces changes in cholecystokinin receptor binding in rat brain. Eur J Pharmacol 180: 77–83

  24. Harro J, Kiivet R-A, Lang A, Vasar E (1990c) Rats with anxious or non-anxious type of exploratory behaviour differ in their brain CCK-8 and benzodiazepine receptor characteristics. Behav Brain Res 39: 63–71

  25. Hughes J, Boden P, Costall B, Domeney AM, Kelly ME, Horwell DC, Hunter JC, Pinnock RD, Woodruff GN (1990) Development of a new class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA. 87: 6728–6732

  26. Leathley MJ, Goudie AJ (1992) Effects of the 5-HT3 antagonist ICS 205–930 on benzodiazepine withdrawal in rats. Behav Pharmacol 3: 51–56

  27. Leathley MJ, Goudie AJ (1993) Effects of the 5-HT2 antagonist ritanserin on benzodiazepine withrawal-induced weight loss in rats. Behav Pharmacol 4: 247–255

  28. Lotti VJ, Chang RSL (1989) A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCKB) ligand: L 365, 260. Eur J Pharmacol 162: 273–280

  29. Meert TF (1992) Ritanserin overcomes exploratory inhibition induced by cocaine withdrawal. Behav Pharmacol 3: 149–154

  30. Mehta AK, Ticku MJ (1993) Ethanol-and diazepam-withdrawal hyperlocomotion is not due to 5-HT3 receptor stimulation. Pharmacol Biochem Behav 45: 755–757

  31. Powell KR, Barrett JE (1991) Evaluation of the effects of PD1343078 (CI-988), a CCK B antagonist, on the punished responding of squirrel monkeys. Neuropeptides 19 [Suppl]: 75–78

  32. Prather Pl, Rezazadeh SM, Lane JD, Rowan GA, Hooper ML, Lytle DA, Emmett-Oglesby MW, Lal H (1993) Conflicting evidence regarding the efficacy of ondansetron in benzodiazepine withdrawal. J Pharmacol Exp Ther 264: 622–630

  33. Rasmussen K, Helton DR, Berger JE, Scearce E (1993) The CCK B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle. NeuroReport 5: 154–156

  34. Rataud J, Darche F, Piot O, Stutzman JM, Bohme GA, Blanchard J (1991) Anxiolytic effects of CCK-antagonists on plus maze behaviour in mice. Brain Res 548: 1–2

  35. Ravard S, Dourish CT (1990) Cholecystokinin and anxiety. Trends Pharmacol Sci 11: 271–273

  36. Singh L, Lewis AS, Field MJ, Hughes J, Woodruff GN (1991a) Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc Natl Acad Sci USA 88: 1130–1133

  37. Singh L, Field MJ, Hughes J, Menzies R, Oles RJ, Vass CA, Woodruff GN (1991b) The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist. Br J Pharmacol 104: 239–245

  38. Singh L, Field MJ, Vass CA, Hughes J, Woodruff GN (1992) Antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988. Br J Pharmacol 105: 8–10

  39. Vivian JA, Farrell WJ, Sapperstein SB, Miczek KA (1994) Diazepam withdrawal: effects of diazepam and gepirone on acoustic startle-induced 22 kHz ultrasonic vocalisations. Psychopharmacology 114: 101–108

  40. Woodruff GN, Hughes J (1991) Cholecystokinin antagonists. Annu Rev Pharmacol Toxicol 31: 469–501

Download references

Author information

Correspondence to A. J. Goudie.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Goudie, A.J., Leathley, M.J. Effects of the CCKB antagonist L-365, 260 on benzodiazepine withdrawal-induced hypophagia in rats. Psychopharmacology 118, 57–64 (1995).

Download citation

Key words

  • CCKB antagonists
  • L-365, 260 Benzodiazepines
  • Chlordiazepoxide
  • Withdrawal Anxiety
  • Food Intake
  • Hypophagia
  • Rats